Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection

Infection and Immunity

Volumn 77, Issue 12, 2009, Pages 5496-5500

  Arakawa, Takeshi ^a   Tachibana, Mayumi ^b   Miyata, Takeshi ^a   Harakuni, Tetsuya ^a   Kohama, Hideyasu ^a   Matsumoto, Yasunobu ^c   Tsuji, Naotoshi ^d   Hisaeda, Hajime ^e,g   Stowers, Anthony ^e,h   Torii, Motomi ^b   Tsuboi, Takafumi ^f  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f EHIME UNIVERSITY   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; MALARIA VACCINE; MEMBRANE PROTEIN; OOKINETE SURFACE PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOPHELES STEPHENSI; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; OOCYST; PARASITE DEVELOPMENT; PARASITE TRANSMISSION; PASSIVE IMMUNIZATION; PLASMA TRANSFUSION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANOPHELES; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHOLERA TOXIN; DISEASE VECTORS; FEMALE; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED DBA; PLASMODIUM YOELII; PROTOZOAN PROTEINS;

EID: 72449170498     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00640-09     Document Type: Article

References (28)

1. Agren, L. C., L. Ekman, B. Löwenadler, and N. Y. Lycke. 1997. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158:3936-3946.
2. Arakawa, T., A. Komesu, H. Otsuki, J. Sattabongkot, R. Udomsangpetch, Y. Matsumoto, N. Tsuji, Y. Wu, M. Torii, and T. Tsuboi. 2005. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect. Immun. 73:7375-7380.
3. Arakawa, T., T. Tsuboi, A. Kishimoto, J. Sattabongkot, N. Suwanabun, T. Rungruang, Y. Matsumoto, N. Tsuji, H. Hisaeda, A. Stowers, I. Shimabukuro, Y. Sato, and M. Torii. 2003. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine 21:3143-3148.
4. Carter, R. 2001. Transmission blocking malaria vaccines. Vaccine 19:2309-2314.
5. del Carmen Rodriguez, M., P. Gerold, J. Dessens, K. Kurtenbach, R. T. Schwartz, R. E. Sinden, and G. Margos. 2000. Characterisation and expression of pbs25, a sexual and sporogonic stage specific protein of Plasmodium berghei. Mol. Biochem. Parasitol. 110:147-159.
6. Escalante, A. A., A. A. Lal, and F. J. Ayala. 1998. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics 149:189-202.
7. Genton, B. 2008. Malaria vaccines: a toy for travelers or a tool for eradication? Expert Rev. Vaccines 7:597-611.
8. Gozar, M. M., O. Muratova, D. B. Keister, C. R. Kensil, V. L. Price, and D. C. Kaslow. 2001. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. Exp. Parasitol. 97:61-69.
9. Gozar, M. M., V. L. Price, and D. C. Kaslow. 1998. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect. Immun. 66:59-64.
10. Greenwood, B. 2008. Can. malaria be eliminated? Trans. R. Soc. Trop. Med. Hyg. 103S:S2-S5.
11. Greenwood, B. M., D. A. Fidock, D. E. Kyle, S. H. Kappe, P. L. Alonso, F. H. Collins, and P. E. Duffy. 2008. Malaria: progress, perils, and prospects for eradication. J. Clin. Investig. 118:1266-1276.
12. Hafalla, J. C., M. L. Santiago, M. C. Pasay, B. L. Ramirez, M. M. Gozar, A. Saul, and D. C. Kaslow. 1997. Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 87:97-99.
13. Harakuni, T., H. Kohama, M. Tadano, G. Uechi, N. Tsuji, Y. Matsumoto, T. Miyata, T. Tsuboi, H. Oku, and T. Arakawa. 2009. Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus. Jpn. J. Infect. Dis. 62:37-45.
14. Hisaeda, H., A. W. Stowers, T. Tsuboi, W. E. Collins, J. S. Sattabongkot, N. Suwanabun, M. Torii, and D. C. Kaslow. 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68:6618-6623.
15. Holmgren, J., J. Adamsson, F. Anjuère, J. Clemens, C. Czerkinsky, K. Eriksson, C. F. Flach, A. George-Chandy, A. M. Harandi, M. Lebens, T. Lehner, M. Lindblad, E. Nygren, S. Raghavan, J. Sanchez, M. Stanford, J. B. Sun, A. M. Svennerholm, and S. Tengvall. 2005. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. 97:181-188.
16. Holmgren, J., and C. Czerkinsky. 2005. Mucosal immunity and vaccines. Nat. Med. 11:S45-53.
17. Kaslow, D. C. 1997. Transmission-blocking vaccines: uses and current status of development. Int. J. Parasitol. 27:183-189.
18. Kaslow, D. C., C. Bathurst, T. Lensen, T. Ponnudurai, P. J. Barr, and D. B. Keister. 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun. 62:5576-5580.
19. Kaslow, D. C., I. A. Quakyi, and D. B. Keister. 1989. Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. Mol. Biochem. Parasitol. 32:101-103.
20. Richie, T. L., and A. Saul. 2002. Progress and challenges for malaria vaccines. Nature 415:694-701.
21. Saul, A. 2008. Efficacy model for mosquito stage transmission blocking vaccines for malaria. Parasitology 135:1497-1506.
22. Seder, R. A., and A. V. Hill. 2000. Vaccines against intracellular infections requiring cellular immunity. Nature 406:793-798.
23. Shi, Y. P., M. P. Alpers, M. M. Povoa, and A. A. Lal. 1992. Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 50:179-180.
24. Stowers, A. W., D. B. Keister, O. Muratova, and D. C. Kaslow. 2000. A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies. Infect. Immun. 68:5530-5538.
25. Tsuboi, T., Y. M. Cao, Y. Hitsumoto, T. Yanagi, H. Kanbara, and M. Torii. 1997. Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity. Infect. Immun. 65:2260-2264.
26. Tsuboi, T., Y. M. Cao, M. Torii, Y. Hitsumoto, and H. Kanbara. 1995. Murine complement reduces infectivity of Plasmodium yoelii to mosquitoes. Infect. Immun. 63:3702-3704.
27. Tsuboi, T., O. Kaneko, Y. M. Cao, M. Tachibana, Y. Yoshihiro, T. Nagao, H. Kanbara, and M. Torii. 2004. A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28. Parasitol. Int. 53:211-216.
28. Tsuboi, T., D. C. Kaslow, M. M. Gozar, M. Tachibana, Y. M. Cao, and M. Torii. 1998. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 4:772-782.